Second in the series as we open our cyber risk dataset; how we bootstrapped more robust breach records with an annotation toolchain for Center for Internet Security (CIS) controls and loss info for modeling severity to drive FAIR Institute Cyber Risk Quantification models buff.ly/2RVfUMH

The global financial services institutions spend as much as $100B each year on compliance. #KYC due diligence and #AML screenings are the largest items on the total #compliance bill, collectively accounting for ~32%. hubs.ly/H0j_kR40

For every RETWEET OF THIS TWEET we will donate $1 to Children’s Oncology Group. Today is the last day to help us #KickChildhoodCancer. GO GO GO! 💛

Excited to recently have joined HealthMode and they've just published a great paper on how we've built a dataset of cough audio using clips from YouTube. Great stuff!

Sensors & AI can now spot low blood sugar without needles, wearable monitoring devices are under federal investigation for alleged patent violations, and you can now download an app to keep track of your bowel patterns. Read the latest #digitalhealth news! buff.ly/30KDbFG

At HealthMode, we used smartphones for continuous data collection to measure cough. High resulting sensitivity to cough promises a path to a new cough measuring tool right in patients’ pockets. Would your patients like such an app? buff.ly/2unzaed

Measuring not only the decision ability but also *how* patients with Alzheimer’s interact with an app analyzing cognitive impairment will provide further insights to the progression of dementia. Looking forward to work on this.

A global initiative to tackle the early detection of diseases like Alzheimer’s. "The project will harness and analyze a wealth of digital data to develop signatures of disease that can be then detected using wearable technologies, such as smart watches." edon-initiative.org

HealthMode is conducting one of world’s first virtual research studies of a mobile application to characterize bowel patterns. The work could lead to better therapies and treatment strategies for millions of people world-wide who suffer from GI diseases. buff.ly/32gFbpJ

Patients often struggle when describing their own coughs to doctors—but #AI could help HealthMode #machinelearning #healthcare #data ow.ly/zA7050ywU7F

Nice initiative: the Machine Learning School in Seville set to happen on March 26-27, will be held as a virtual conference, and will be offered free of charge for those who register. Great program for those who are in forced quarantine/holidays.

Really proud to be part of the effort to understand this disease. Looking forward to get better insights, and understand the consequences for the general population

As the #coronavirus pandemic sweeps across the globe, HealthMode has launched a #clinicaltrial to see if cough sound analytics can predict the clinical course of COVID-19. Read more >> buff.ly/3cojFU5

HealthMode is pleased to bring our digital pain measure to this important clinical trial with WinSanTor helping to advance research of a therapy that may help so many who suffer the pain of peripheral neuropathy. buff.ly/3bxt0aY

We are pleased to bring our new cough measure and #digitalbiomarker expertise to power Sema4 Works. buff.ly/30ABzi6

HealthMode conducted one of the world’s first remote research studies using a smartphone app to characterize bowel patterns in the adult population. Read what we learned in the process buff.ly/33MgEKA

Looking forward to work on next-gen measurements for psychedelic medicines at mindmedco prnewswire.com/news-releases/…

This is very exciting stuff. We're about to start a large data collection effort on mental illnesses. The biggest hurdle in this space is lack of data, and this is the first major step in the path for providing better biomarkers for mental health. mindmed.co/news/press-rel…

As #mentalhealth suffering continues to soar, #psychedelics are on the cusp of entering mainstream medicine. Vote to see MindMed CEO Rob Barrow at #SXSW2024 discussing the captivating journey of LSD, from stigma to curiosity to the hope of healing: bit.ly/3qp3tyq

Today, we announced the FDA has granted breakthrough therapy designation for MM120 in GAD. We also announced positive 12-week durability data from our Phase 2b study of MM120 in GAD and are hosting a call at 8AM ET to discuss details. Read more: brnw.ch/21wHEzM $MNMD